luspatercept

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

β-Thalassemia

Conditions

β-Thalassemia

Trial Timeline

Oct 20, 2014 → Jun 18, 2020

NCT ID

NCT02268409

About luspatercept

luspatercept is a phase 2 stage product being developed by Merck for β-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02268409. Target conditions include β-Thalassemia.

What happened to similar drugs?

1 of 2 similar drugs in β-Thalassemia were approved

Approved (1) Terminated (1) Active (1)

✅DeferasiroxNovartisApproved

🔄DeferasiroxNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03342404	Phase 2	Completed	Feb 5, 2018	Nov 28, 2022	Thalassemia
NCT02604433	Phase 3	Completed	May 2, 2016	Jan 5, 2021	Erythrocyte Transfusion
NCT02631070	Phase 3	Completed	Feb 9, 2016	Nov 26, 2020	Myelodysplastic Syndromes
NCT02268409	Phase 2	Completed	Oct 20, 2014	Jun 18, 2020	β-Thalassemia
NCT02268383	Phase 2	Completed	Oct 9, 2014	Mar 19, 2020	Myelodysplastic Syndromes
NCT01749540	Phase 2	Completed	Feb 28, 2013	Nov 11, 2015	B-Thalassemia
NCT01749514	Phase 2	Completed	Jan 21, 2013	Oct 22, 2018	Anemia

Competing Products

8 competing products in β-Thalassemia

See all competitors

Product	Company	Stage	Hype Score
Deferasirox	Novartis	Approved	35
Deferasirox + Deferoxamine (DFO)	Novartis	Phase 2	27
Deferasirox	Novartis	Phase 1	29
Deferasirox	Novartis	Phase 3	40
Luspatercept	Bristol Myers Squibb	Pre-clinical	30
Luspatercept	Bristol Myers Squibb	Pre-clinical	33
PTG-300	Protagonist Therapeutics	Phase 2	32
PTG-300	Protagonist Therapeutics	Phase 2	32